Wang M - Search Results

1

Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides.

Zhao Y, Wang S, Fei W, Feng Y, Shen L, Yang X, Wang M, Wu M. Zhao Y, et al. Among authors: wang m, wang s. Int J Mol Sci. 2021 May 26;22(11):5630. doi: 10.3390/ijms22115630. Int J Mol Sci. 2021. PMID: 34073203 Free PMC article.

2

MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.

Xu Z, Wang Z, Jia X, Wang L, Chen Z, Wang S, Wang M, Zhang J, Wu M. Xu Z, et al. Among authors: wang l, wang z, wang m, wang s. Cancer Lett. 2016 Mar 1;372(1):118-27. doi: 10.1016/j.canlet.2015.12.025. Epub 2015 Dec 29. Cancer Lett. 2016. PMID: 26739060

3

A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.

Jia X, Wang W, Xu Z, Wang S, Wang T, Wang M, Wu M. Jia X, et al. Among authors: wang w, wang m, wang t, wang s. Sci Rep. 2016 Jun 15;6:27985. doi: 10.1038/srep27985. Sci Rep. 2016. PMID: 27301650 Free PMC article.

4

The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.

Wang S, Zhou R, Sun F, Li R, Wang M, Wu M. Wang S, et al. Among authors: wang m. Cancer Lett. 2017 Nov 28;409:125-136. doi: 10.1016/j.canlet.2017.09.004. Epub 2017 Sep 18. Cancer Lett. 2017. PMID: 28923397

5

The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.

Zhou R, Wang S, Wen H, Wang M, Wu M. Zhou R, et al. Among authors: wang m, wang s. Exp Cell Res. 2019 Jul 15;380(2):141-148. doi: 10.1016/j.yexcr.2019.04.025. Epub 2019 Apr 26. Exp Cell Res. 2019. PMID: 31034805

6

Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Wang S, Wen H, Fei W, Zhao Y, Feng Y, Kuang L, Wang M, Wu M. Wang S, et al. Among authors: wang m. Am J Cancer Res. 2020 Aug 1;10(8):2387-2408. eCollection 2020. Am J Cancer Res. 2020. PMID: 32905508 Free PMC article.

7

Erratum: Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Wang S, Wen H, Fei W, Zhao Y, Feng Y, Kuang L, Wang M, Wu M. Wang S, et al. Among authors: wang m. Am J Cancer Res. 2022 Jun 15;12(6):2893-2896. eCollection 2022. Am J Cancer Res. 2022. PMID: 35812052 Free PMC article.

8

Recombinant Reg3α Prevents Islet β-Cell Apoptosis and Promotes β-Cell Regeneration.

Yu L, Li L, Liu J, Sun H, Li X, Xiao H, Alfred MO, Wang M, Wu X, Gao Y, Luo C. Yu L, et al. Among authors: wang m. Int J Mol Sci. 2022 Sep 13;23(18):10584. doi: 10.3390/ijms231810584. Int J Mol Sci. 2022. PMID: 36142497 Free PMC article.

9

An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo.

Xu HM, Yin R, Chen L, Siraj S, Huang X, Wang M, Fang H, Wang Y. Xu HM, et al. Among authors: wang y, wang m. Bioconjug Chem. 2008 Oct;19(10):1980-6. doi: 10.1021/bc800132p. Epub 2008 Sep 19. Bioconjug Chem. 2008. PMID: 18800818

10

The mAb against adipocyte fatty acid-binding protein 2E4 attenuates the inflammation in the mouse model of high-fat diet-induced obesity via toll-like receptor 4 pathway.

Miao X, Wang Y, Wang W, Lv X, Wang M, Yin H. Miao X, et al. Among authors: wang w, wang y, wang m. Mol Cell Endocrinol. 2015 Mar 5;403:1-9. doi: 10.1016/j.mce.2014.12.017. Epub 2015 Jan 14. Mol Cell Endocrinol. 2015. PMID: 25596549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68,638 results

Search Page

Filters